Aug 9, 2023 | Business
USPA Global Licensing Inc. (USPAGL) today announced that U.S. Polo Assn., the official brand of the United States Polo Association (USPA), climbed License Global magazine’s prestigious list of 2023’s Top Global Licensors and for the first time ever is ranked in the top 25. The multi-billion-dollar, sport-inspired brand moved up three spots from 28th in 2022 to 25th overall and is considered one of the largest sports licensors and apparel licensors in the world. The iconic brand was also ranked as the second-largest sports brand, alongside the NFL and PGA Tour.
U.S. Polo Assn.’s strong ratings come off an outstanding 2022, having achieved $2.3 billion in global retail sales, expanding its footprint to include over 190 countries, and ending the year with more than 1,100 U.S. Polo Assn. retail stores worldwide. The brand’s fast-tracked digital strategy resulted in websites for more than 40 countries in 20 different languages and the activation of more than 7 million social media followers of the brand worldwide. U.S. Polo Assn.’s authentic connection to the sport of polo is resonating with younger consumers and sports fans around the world.
“I want to personally thank all members of our global team and strategic partners around the world on behalf of U.S. Polo Assn. for their hard work and dedication to our sport-inspired brand,” says J. Michael Prince, President and CEO of USPAGL, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. “To be in the top 25 on License Global’s prestigious list and be ranked among other iconic sport and fashion leaders is an honor and a nod to our tireless efforts in executing on our global strategy and aggressive growth plans.”
License Global’s Top Global Licensors list is a “who’s who” of licensing titans, derived from an annual study that “accounts for retail sales of licensed merchandise across all major sectors of business, from entertainment to sport, food and beverage, corporate brands, fashion, art and design, and much more.”
To be considered for inclusion, each brand or corporate entity must submit retail figures based on worldwide sales of licensed merchandise. In addition, License Global’s editors do their own independent vetting and verification, by consulting industry sources, annual reports, and financial documents. The world’s largest brand remains The Walt Disney Company at $61.7 billion in retail sales, with the third-largest brand, Warner Bros. Discovery, at $15.8 billion, and Mattel, the eighth-largest brand at $8 billion.
About U.S. Polo Assn. and USPA Global Licensing Inc. (USPAGL)
U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the non-profit governing body for the sport of polo in the United States and one of the oldest sports governing bodies, having been founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through over 1,100 U.S. Polo Assn. retail stores and thousands of department stores, sporting goods channels, independent retailers, and e-commerce, U.S. Polo Assn. offers apparel for men, women, and children, as well as accessories and footwear in more than 190 countries worldwide. U.S. Polo Assn. was named one of the top global sports licensors in 2023, according to License Global. Visit uspoloassnglobal.com and follow @uspoloassn.
USPA Global Licensing Inc. (USPAGL) is the for-profit subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand, providing the sport with a long-term source of revenue. Through its subsidiary, Global Polo Entertainment (GPE), USPAGL also manages Global Polo TV, which provides sport and lifestyle content. A historic, multi-year, global arrangement between USPAGL and ESPN, now showcases many of the top championship polo games in the U.S., enabling millions of sports fans and consumers to enjoy the sport across ESPN’s broadcast and streaming platforms. For more sport content, visit globalpolo.com.
Contact Information:
Stacey Kovalsky
Senior Director, Global Communications
skovalsky@uspagl.com
+001.561.790.8036
Shannon Stilson
VP, Sports Marketing & Media
sstilson@uspagl.com
+001.561.227.6994
Gina Digregorio
Head of Marketing, Brand Machine Group
gina.digregorio@brandmachinegroup.com
+44 (0) 7741 635 984
Topic: Press release summary
Mar 1, 2023 | Business
Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.
In China, Eisai initiated submission of data for the BLA to the NMPA in December 2022. Eisai initially submitted a package that includes data from the Phase II clinical trial (Study 201) and the top-line data of the large global Phase III Clarity AD study in mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed Aβ accumulation in the brain. Eisai will submit additional data including full data of the Clarity AD study, as directed by the NMPA.
Lecanemab selectively binds and eliminates soluble, toxic Abeta aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference, and simultaneously published in the New England Journal of Medicine(New Window), a peer-reviewed medical journal.
In the U.S., lecanemab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. In Europe, Eisai submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) on January 9, 2023, which was accepted on January 26, 2023. In Japan, Eisai submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023, and Priority Review was designated by the Ministry of Health, Labour and Welfare (MHLW) on January 26, 2023.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
Media Contacts:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Biogen Inc.
Natacha Gassenbach
+ 1-857-777-6573
public.affairs@biogen.com
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Apr 25, 2022 | Business
Mitsubishi Heavy Industries Engineering, Ltd. (MHIENG), a Mitsubishi Heavy Industries (MHI) Group company based in Yokohama, has agreed to license its carbon capture technology and provide the process design package (PDP) for the foreseen phase 1 of Italy’s first CCUS (Carbon dioxide Capture, Utilization and Storage) project being developed by Eni S.p.A., the biggest integrated energy company in Italy. The phase 1 of the project targets the capture of approximately 25,000 tons of CO2 per year from the turbo compressor exhaust operating at Eni’s natural gas plant located in Casalborsetti (Ravenna), in Northeast Italy.
MHIENG’s role in the project will be to provide licensing for its carbon capture technology, the KM CDR Process, jointly developed with The Kansai Electric Power Co., Inc., which is a technology that captures the CO2 contained in flue gas by a process of chemical absorption using MHIENG’s proprietary KS-1 solvent. This system has already been deployed at 13 commercial facilities around the world, where its high reliability has been confirmed by solid track records. MHIENG will provide its carbon capture technology through NextChem S.p.A., green chemistry-dedicated subsidiary of Marie Tecnimont Group, a leading Italian engineering company engaged in the transformation of natural resource as well as in industrializing technologies to support the energy transition.
The new agreement marks MHIENG’s first provision of its carbon capture technology to Italy and has extreme significance in terms of enhancing its presence in Europe. It will also serve as a springboard for MHI Group as a whole, with MHIENG continuing to work in alliance with Mitsubishi Heavy Industries EMEA, Ltd. (MHI-EMEA) – MHI’s regional headquarters for Europe, the Middle East and Africa – to respond to demand in Italy and throughout Europe to advance the energy transition and achieve a carbon neutral society.
MHI Group is currently strengthening its position in the energy transition, and development of a CO2 ecosystem is a core component of that initiative. CCUS is garnering attention as an effective means for realizing a carbon neutral society. Going forward, MHIENG will continue to contribute toward reducing greenhouse gas emissions on a global scale by promoting broad adoption of high-performance CO2 capture technology worldwide. It will also press ahead in developing new proprietary technologies to protect the global environment.
About MHIENG’s CO2 capture technologies
MHIENG (originally MHI) has been developing the KM CDR Process and the Advanced KM CDR Process in collaboration with Kansai Electric Power since 1990. Today MHIENG stands as a global leader in this field. As of April 2022, the KM CDR Process has been adopted at 13 plants worldwide, and three more are currently under construction. For further details, visit the following website and view the attached video presentation. https://www.mhi.com/products/engineering/co2plants.html
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com.
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
